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Sensorimotor symptoms Autonomic symptoms Cardiac symptoms
Sensory loss Orthostatic disorder Arrythmia
Pain Weight loss Heart blocks
Numbness Alternating diarrhoea and 
constipation
Cardiac insufficiency 
Muscle weakness Erectile dysfunction
Impaired thermal  
sensibility of the feet
Table 1. Clinical symptoms of TTR-FAP, sensorimotor symptoms 
occur in general in an early stage of disease 
Table 2. Clinical staging system as described by Coutinho et al. [3] 
Familial amyloidosis 
Signs and symptoms Stage 1 Stage 2 Stage 3 
Motor Mild Mild/moderate Severe 
Limb involvement Lower Lower/upper Lower/upper 
Autonomic Mild Moderate Severe 
Activities of daily living None/minimal Significant Profound 
Ambulation No assistance 
required 
Assistance 
required
Wheelchair/ 
bed-bound 
Treatment Mode of action Type of clinical trial Administration Dosage No. of 
patients
Included 
mutations
Authorization Ref.
Tafamidis TTR stabilizer Phase III through 2009 p.o. 20 mg daily 128 Val30Met yes, EMA [11]
Diflunisal TTR stabilizer phase II/III 
through 2012
p.o. 250 mg twice/day 130 no [12]
siRNA Gene silencing Phase III current i.v. n.a. n.a. n.a.
Phase I/II through 2012 i.v. ALT-TTR01: 0.01-1 mg per kg 
body weight; ALN-TTR02: 0.01-
0.5 mg per kg body weight
49 Val30Met, 
Ser77Tyr, 
Ser77Phe
no [14]
ISIS-TTRRX Antisense oligonucleotide Preclinical s.c [13]
Phase I current s.c. n.a. n.a. n.a. no
Table 3. 
Overview 
treatment and 
clinical trials in 
FAP 
p.o. : per oral; i.v.: intravenously; s.c. subcutaneously; n.a.: not analysed; EMA: European Medical Authority
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Familial amyloidosis (synonym for familiar amyloid polyneuropathy 
[FAP]) is an autosomal dominant inherited disease, caused by 
mutations in the transthyretin (TTR) gene, coding for the corresponding 
protein consisting of 127 amino acids. It was first described by the 
Portuguese neurologist Andrade. The TTR gene is located on 
chromosome 18q. More than 100 different mutations are known. The 
most common mutation is the Val30Met mutation, endemically found 
in Portugal, Sweden, and Japan. Among the other mutant proteins that 
are of etiological importance but are very rare, is apolipoprotein I and 
II, or fibrinogen A. Transthyretin is a tetramer, built out of four identical 
TTR-subunits [1]. Point mutations of the gene lead to a destabilization 
of the protein and subsequently to protein misfolding, resulting in 
the extracellular deposition of mutated amyloid in several tissues, 
predominantly in peripheral/autonomic nerves, gastrointestinal tract 
and myocardium [2].
  The onset of symptoms is highly variable, depending on the underlying 
mutation, and occurs between 25 and >50 years. Regarding the course 
of the disease, patients with an early-onset have to be distinguished 
from late-onset patients, predominantly living in non-endemic countries 
like France, UK or Germany. The most common clinical symptoms 
are given in Table 1. Coutinho et al. established a staging system 
with three stages of the disease depending on the progression of 
walking disability and immobility [3] (Table 2). This scoring system fits 
predominantly for patients with an early-onset of disease. Patients with 
a late-onset of FAP show a more rapid progression, more functional 
impairment and lower survival. The prognosis of FAP is dismal and, 
if left untreated, results in death within 10 years after diagnosis [4]. 
Diagnosis of amyloidosis is most frequently performed histologically 
by detecting amyloid deposits in various tissues by Congo red staining 
following immunohistochemistry and genetic testing of the TTR gene.
Therapy of FAP
Therapy is complex and needs a multidisciplinary approach, as clinical 
symptoms are very heterogeneous, depending on the underlying 
mutation and its phenotype. Besides symptomatic therapy, liver 
transplantation (LT) has become the ultimate disease treatment since 
over 95% of the TTR-amyloid is produced in the liver [5]. However, in 
some cases neuropathy and/or cardiomyopathy may progress even 
after LT [6], potentially due to the fact that once amyloid deposits 
have accumulated, formation of fibrils may continue from completely 
normal TTR (wild type TTR). Therefore, LT should be performed at 
an early stage of disease. Also, since outcome after transplantation 
depends on the general condition of the patient, LT outcome in the 
advanced stage of FAP, e.g. with cachexia, or cardiac impairment, 
remains worse [7,8]. In patients with advanced cardiac involvement 
or renal impairment few combined heart and liver or kidney and liver 
transplantations were reported [5,8,9].
Drug therapy of FAP
Stabilizer of transthyretin
Recently, the transthyretin stabilizer Tafamidis was approved by the 
European Medical Authority (EMA) for treatment of early stage FAP 
(stage 1, disease limited to lower limbs, walking without any help). 
Binding of Tafamidis to the T4 binding sites stabilizes the TTR-tetramer 
and dissociation into monomers and amyloidogenic components 
is impeded [10] (Fig. 1). A recent double-blind placebo-controlled 
multicentre study (Fx-005) showed a benefit for stage 1 patients 
on 20 mg Tafamidis per day with respect to neurological symptoms, 
total quality of life and modified body mass index, leading to a slower 
progression of the disease [11] within an observation period of 18 
months. Although all patients were carriers of the Val30Met mutation 
and of predominantly Portuguese origin, the drug was approved for all 
TTR-mutations. Generally, Tafamidis is well-tolerated, most frequent 
side effects were urinary tract infections and diarrhoea. Long-term side 
effects or drug-drug interactions remain to be investigated. Further 
trials, studying an impact of Tafamidis in patients with familial amyloid Journal of Hepatology 20484
Fig. 1. Familial amyloidosis gene defect on chromosome 18q.rdiomyopathy are planned. Due to the high costs of Tafamidis,
eatment should be re-evaluated every 3–6 months and if symptoms 
ogress, e.g. neuropathy or cardiopathy, discontinuation of treatment 
ay be considered [16]. 
erapeutic perspectives on the horizon
iflunisal is a nonsteroidal anti-inflammatory agent, which stabilizes 
R tetramers by binding to their T4-binding sites. In a recently
blished, double-blind, placebo controlled study regarding the 
fect of diflunisal treatment on polyneuropathy progression [12], 130 
tients with detectable peripheral or autonomic neuropathy were 
vestigated, demonstrating a significant reduction of progression of
urological impairment and a preserved quality of life. Although not 
t approved the drug may become an effective and well-tolerated 
eatment alternative.
 Several other therapeutic options are currently investigated. ISIS-
RRX is a second generation antisense oligonucleotide inhibitor
 transthyretin, which binds to the non-translated portion of the 
man TTR-mRNA, resulting in the degradation of TTR-mRNA. Thus,
e translation of wild type and mutant TTR proteins is interrupted.
asibility of this therapeutic approach and a significant plasma TTR
otein level suppression was shown in murine and monkey models 
3]. A phase I clinical trial is currently ongoing.
 Two disease specific lipid nanoparticle formulations of small 
terfering RNAs (siRNAs), ALN-TTR01, and ALN-TTR02 interact with 
ild type TTR (non-mutated) and all mutated TTRs. Intriguingly, the 
RNA is predominantly delivered to the liver, the site of production of
yloid. In a recent phase I study, safety and efficacy of the siRNA
erapy was investigated in 32 patients and 17 healthy volunteers 
4], showing a suppression of TTR by ALN-TTR01 at day 7 of 38%,
mpared with placebo, and a mean reduction in TTR levels for ALN-
R02 of 57% to 67% at day 28. Overall, the concept is promising 
d a phase II study is currently underway. An overview of clinical 
ials regarding therapy in familial amyloidosis is added as Table 3 in 
e Snapshot
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